Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program


April 28, 2026

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart


April 14, 2026

Cardiol Therapeutics Announces Year-End 2025 Update on Operations


April 1, 2026

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference


February 25, 2026

Cardiol Therapeutics’ ARCHER Phase II Study Results Published in ESC Heart Failure


February 10, 2026

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million


January 23, 2026

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million


January 16, 2026

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis


January 13, 2026

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx™ Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions


December 1, 2025

2026 Cardiol Therapeutics. All right reserved.